ID   COLO 677
AC   CVCL_1862
SY   COLO-677; COLO #677; COLO677; Colorado 677
DR   CLO; CLO_0002550
DR   CLDB; cl837
DR   CLDB; cl838
DR   BioSample; SAMN03151910
DR   cancercelllines; CVCL_1862
DR   Cosmic; 753542
DR   DSMZ; ACC-248
DR   DSMZCellDive; ACC-248
DR   ECACC; 93072109
DR   GEO; GSM784242
DR   IARC_TP53; 21233
DR   PharmacoDB; COLO677_225_2019
DR   Progenetix; CVCL_1862
DR   Wikidata; Q54814130
RX   CelloPub=CLPUB00604;
RX   PubMed=11668190;
RX   PubMed=20143388;
RX   PubMed=32123307;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
WW   Info; Keats Lab; -; https://www.keatslab.org/myeloma-cell-lines
CC   Problematic cell line: Contaminated. Shown to be a RPMI-8226 derivative (PubMed=20143388). Originally thought to originate from the lymph nodes of a 50 year old male patient with a small cell lung carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00299.
CC   Population: African American.
CC   Characteristics: Produces IgG lambda (from parent cell line).
CC   Doubling time: ~40 hours (DSMZ=ACC-248).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5722; IGKJ4 + HGNC; HGNC:5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5865; IGLJ3 + HGNC; HGNC:5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (CelloPub=CLPUB00604).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Discontinued: DSMZ; ACC-248; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Plasma cell; CL=CL_0000786.
ST   Source(s): DSMZ=ACC-248
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 15,19
ST   D19S433: 14
ST   D21S11: 28,29
ST   D2S1338: 20
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 19
ST   Penta D: 3,11
ST   Penta E: 16,17
ST   TH01: 8
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0014 ! RPMI-8226
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 36
//
RX   CelloPub=CLPUB00604;
RA   Chow, Sharon
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier, Hilmar
RA   Osborn, Mary
RA   Reinhardt, Julia
RA   Zaborski, Margarete
RA   Drexler, Hans Gunther
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis, Amanda
RA   Theodosopoulos, George
RA   Atkin, Isobel
RA   Drexler, Hans Gunther
RA   Kohara, Arihiro
RA   MacLeod, Roderick A.F.
RA   Masters, John R.W.
RA   Nakamura, Yukio
RA   Reid, Yvonne A.
RA   Reddel, Roger Robert
RA   Freshney, Robert Ian
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin, Vishesh
RA   Yu, Katharine
RA   Ferguson, Ian D.
RA   Gugliemini, Olivia
RA   Nix, Matthew A.
RA   Hann, Byron
RA   Sirota, Marina
RA   Wiita, Arun P.
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//